SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- U.S. Stocks Fall on Dubai Worries

MORE HEADLINES

» Markets | Economy | Companies

- Global Selloff From Dubai Woes Shows Signs of Winding Down

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

May.24

3:16 PM ET

Thursday, 24 May 2007

Lipitor: Loser

Posted By:Mike Huckman

Topics:Medicine | Pharmaceuticals

Companies:Dr. Reddy's Laboratories Ltd | Teva Pharmaceutical Industries Limited | Pfizer Inc | Merck & Co Inc

Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.

Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"

He goes on to write, "Simvastatin Still on Course to Catch Lipitor" (the bold type is his emphasis). "... (Merck's) [MRK Loading... () ] Zocor and simvastatin now hold a 23.9% total prescription share. Lipitor, on the other hand, has declined from a 41.8% total prescription share last year to a 33.5% share now. Unless Pfizer [PFE Loading... () ] can significantly change Lipitor's trajectory it appears to be only a matter of time before simvastatin becomes the market leader in the cholesterol-lowering market."

You may recall that in its first-quarter earnings release, Pfizer said for the first time that Lipitor sales possibly could be down modestly this year. Nonetheless, it is still by far the world's top-selling drug. A bunch of companies, including Israel's Teva Pharmaceuticals [TEVA Loading... () ] and India's Dr. Reddy's Laboratories [RDY Loading... () ], make generic simvastatin.

Tooley's data are based on numbers from IMS Health (a company that monitors prescriptions) and AG Edwards estimates. AGE or one of its officers has a long position in PFE.